BCL2 and breast cancer: Oakes et al. reported that ABT–737 sensitized primary basal-like breast cancers with elevated Bcl-2 levels to docetaxel and improved response and OS in an in vivo setting, suggesting that elevated Bcl-2 expression constitutes a predictive response marker in breast cancer [9].